Mepolizumab: 15 agencies, 2015–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA671, while PBAC (Australia) recorded not recommended for “Severe eosinophilic asthma”.
HAS (France) has been harder on mepolizumab than on its own caseload: it refused 4 of 9 decisive submissions here (44%), against a base rate of 11% across everything it has assessed.
Assessment has run over 10.8 years, from 13 Oct 2015 at AWMSG (Wales) to 7 Jul 2026 at TLV (Sweden).
TLV (Sweden) changed its position: not recommended on 3 Jun 2016, restricted by 7 Jul 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for mepolizumab.
Not every gap is a refusal: for mepolizumab, 3 submissions were never made and 4 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 16 of 59 records date from 2023 or later.
The programme is broad: 17 distinct indication wordings are recorded for mepolizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
10 of these 59 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess mepolizumab, on 13 Oct 2015; AOTMIT (Poland) did not open a file until 5 Jul 2024 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 12 years in total.
12 of the 15 agencies here assessed mepolizumab more than once, PBAC (Australia) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
mepolizumab has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for mepolizumab reads 26 recommended, 9 restricted, 8 not recommended and 3 terminated, with 13 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2026 | Chronic obstructive pulmonary disease (COPD) | Recommended | source |
| NICE (England) | 17 Jun 2026 | NICE TA1166 | published appraisal | source |
| HIRA (South Korea) | 15 Jan 2026 | 성인 및 청소년 (12 세 이상 ) 에서 기존 치료에 적절하게 조절되지 않는 중증 호산구성 천식 (SEA) 치료의 추가 유지 요법 | reimbursable only at the evaluated price | source |
| PHARMAC (New Zealand) | 24 Jan 2025 | Chronic rhinosinusitis with nasal polyps (CRSwNP), after one nasal polyp surgery unless surgery is contraindicated | PTAC advice: High | source |
| SMC (Scotland) | 9 May 2022 | As add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause. | not recommended | source |
54 further decisions for mepolizumab, across 15 agencies, are not shown here. They include the most recent record on file, 7 Jul 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 38 further source documents.
Related molecules
- omalizumab — same ATC class R03D — Obstructive airway diseases
- benralizumab — same ATC class R03D — Obstructive airway diseases
- tezepelumab — same ATC class R03D — Obstructive airway diseases
- montelukast — same ATC class R03D — Obstructive airway diseases
- depemokimab — same ATC class R03D — Obstructive airway diseases
- roflumilast — same ATC class R03D — Obstructive airway diseases
Coverage: 59 decisions for mepolizumab from 15 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class R03D — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.